Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues

FEBS Journal

Volumn 275, Issue 22, 2008, Pages 5479-5495

  Cheung, Lydia W T ^a   Wong, Alice S T ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cross talk; Extrapituitary; GnRH; GnRH receptor; MAPK; Metastasis; Pituitary; Receptor tyrosine kinase; Signaling; Tumor

Indexed keywords

ACTIN; CETRORELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INTEGRIN; IODINE 125; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANGIOGENESIS; BREAST TUMOR; CANCER INVASION; CELL PROLIFERATION; CYTOSKELETON; DOSE RESPONSE; DRUG MECHANISM; ENDOMETRIUM TUMOR; GONADOTROPIN SECRETING CELL; HORMONE ACTION; HUMAN; HYPOPHYSIS; METASTASIS; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

GONADOTROPIN-RELEASING HORMONE; HUMANS; NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION;

EID: 54849408590     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06677.x     Document Type: Short Survey

References (150)

1. Chen A, Yahalom D, Ben-Aroya N, Kaganovsky E, Okon E Koch Y (1998) A second isoform of gonadotropin-releasing hormone is present in the brain of human and rodents. FEBS Lett 435, 199 203.
2. White RB, Eisen JA, Kasten TL Fernald RD (1998) Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 95, 305 309.
3. Densmore VS Urbanski HF (2003) Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J Clin Endocrinol Metab 88, 2126 2134.
4. Kauffman AS (2004) Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour. J Neuroendocrinol 16, 794 806.
5. Schally AV, Comaru-Schally AM Redding TW (1984) Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med 175, 259 281.
6. Peng C, Fan NC, Ligier M, Vaananen J Leung PC (1994) Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 135, 1740 1746.
7. Brus L, Lambalk CB, de Koning J, Helder MN, Janssens RM Schoemaker J (1997) Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 12, 769 773.
8. Choi JH, Gilks CB, Auersperg N Leung PC (2006) Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 91, 4562 4570.
9. Choi KC, Auersperg N Leung PC (2001) Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 86, 5075 5078.
10. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25, 215 221.
11. Chien CH, Chen CH, Lee CY, Chang TC, Chen RJ Chow SN (2004) Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. Int J Gynecol Cancer 14, 451 458.
12. Cheung LW, Leung PC Wong AS (2006) Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66, 10902 10910.
13. Chen CL, Cheung LW, Lau MT, Choi JH, Auersperg N, Wang HS, Wong AS Leung PC (2007) Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine 31, 311 320.
14. Srkalovic G, Wittliff JL Schally AV (1990) Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50, 1841 1846.
15. Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG Gallagher CJ (1996) The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 56, 2059 2065.
16. Imai A, Ohno T, Iida K, Fuseya T, Furui T Tamaya T (1994) Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 55, 144 148.
17. Marinaccio M, Reshkin S, Pinto V Paradiso A (1994) The estimation of LHRH receptors in the tissue of human leiomyoma, myometrium and endometrium. Minerva Ginecol 46, 519 526.
18. Iwashita M, Evans MI Catt KJ (1986) Characterization of a gonadotropin-releasing hormone receptor site in term placenta and chorionic villi. J Clin Endocrinol Metab 62, 127 133.
19. Casan EM, Raga F Polan ML (1999) GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod 5, 234 239.
20. Boyle TA, Belt-Davis DI Duello TM (1998) Nucleotide sequence analyses predict that human pituitary and human placental gonadotropin-releasing hormone receptors have identical primary structures. Endocrine 9, 281 287.
21. Lin LS, Roberts VJ Yen SS (1995) Expression of human gonadotropin- releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 80, 580 585.
22. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A Counis R (1997) The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 71, 595 599.
23. Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H Sasano H (2001) Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathol Int 51, 333 337.
24. Eidne KA, Flanagan CA, Harris NS Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64, 425 432.
25. Eidne KA, Flanagan CA Millar RP (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 229, 989 991.
26. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M Motta M (1999) The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140, 5250 5256.
27. Tieva A, Stattin P, Wikstrom P, Bergh A Damber JE (2001) Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 47, 276 284.
28. Straub B, Muller M, Krause H, Schrader M, Goessl C, Heicappell R Miller K (2001) Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 7, 2340 2343.
29. Kakar SS, Grizzle WE Neill JD (1994) The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 106, 145 149.
30. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD Schally AV (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77, 1458 1464.
31. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53, 5439 5446.
32. Segal-Abramson T, Kitroser H, Levy J, Schally AV Sharoni Y (1992) Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 89, 2336 2339.
33. Qayum A, Gullick W, Clayton RC, Sikora K Waxman J (1990) The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 62, 96 99.
34. Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knuppen R Emons G (1991) Specific low affinity binding sites for gonadotropin-releasing hormone in human endometrial carcinomata. Eur J Obstet Gynecol Reprod Biol 41, 135 142.
35. Thompson MA, Adelson MD Kaufman LM (1991) Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72, 1036 1041.
36. Volker P, Grundker C, Schmidt O, Schulz KD Emons G (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186, 171 179.
37. Connor JP, Buller RE Conn PM (1994) Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol Oncol 54, 80 86.
38. Slotman BJ, Poels LG Rao BR (1989) A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment. Anticancer Res 9, 77 80.
39. Arencibia JM Schally AV (2000) Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int J Oncol 16, 1009 1013.
40. Gunthert AR, Grundker C, Bottcher B Emons G (2004) Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells. Anticancer Res 24, 1727 1732.
41. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B Emons G (2004) Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151, 141 149.
42. Grundker C, Gunthert AR, Millar RP Emons G (2002) Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87, 1427 1430.
43. Kim KY, Choi KC, Auersperg N Leung PC (2006) Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13, 211 220.
44. Yano T, Pinski J, Radulovic S Schally AV (1994) Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91, 1701 1705.
45. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K Schally AV (1994) Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91, 7090 7094.
46. Schally AV (1999) Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20, 1247 1262.
47. Imai A, Takagi A, Horibe S, Takagi H Tamaya T (1998) Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol 13, 97 100.
48. Kleinman D, Douvdevani A, Schally AV, Levy J Sharoni Y (1994) Direct growth inhibition of human endometrial cancer cells by the gonadotropin- releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol 170, 96 102.
49. Limonta P, Dondi D, Moretti RM, Maggi R Motta M (1992) Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75, 207 212.
50. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E Motta M (1994) Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54, 4091 4095.
51. Montagnani Marelli M, Moretti RM, Dondi D, Limonta P Motta M (1997) Effects of LHRH agonists on the growth of human prostatic tumor cells: 'in vitro' and 'in vivo' studies. Arch Ital Urol Androl 69, 257 263.
52. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M Schally AV (1997) Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 33, 1141 1148.
53. Kraus S, Levy G, Hanoch T, Naor Z Seger R (2004) Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64, 5736 5744.
54. Enomoto M, Seong JY, Kawashima S Park MK (2004) Proliferation of TSU-Pr1, a human prostatic carcinoma cell line is stimulated by gonadotropin-releasing hormone. Life Sci 74, 3141 3152.
55. Enomoto M, Endo D, Kawashima S Park MK (2004) Human type II GnRH receptor mediates effects of GnRH on cell proliferation. Zool Sci 21, 763 770.
56. Miller WR, Scott WN, Morris R, Fraser HM Sharpe RM (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231 233.
57. Gunthert AR, Grundker C, Olota A, Lasche J, Eicke N Emons G (2005) Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 153, 613 625.
58. Sharoni Y, Bosin E, Miinster A, Levy J Schally AV (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86, 1648 1651.
59. Raga F, Casan EM, Wen Y, Huang HY, Bonilla-Musoles F Polan ML (1999) Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab 84, 636 642.
60. Chou CS, Zhu H, Shalev E, MacCalman CD Leung PC (2002) The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. J Clin Endocrinol Metab 87, 5594 5603.
61. Moretti RM, Montagnani Marelli M, Van Groeninghen JC Limonta P (2002) Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 87, 3791 3797.
62. Moretti RM, Monagnani Marelli M, van Groeninghen JC, Motta M Limonta P (2003) Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression. Endocr Relat Cancer 10, 161 167.
63. Hierowski MT, Wettler O Schally AV (1984) Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH. Biomed Pharmacother 38, 297 303.
64. Dondi D, Festuccia C, Piccolella M, Bologna M Motta M (2006) GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 15, 393 400.
65. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN Leung HY (2005) Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206, 205 213.
66. Yates C, Wells A Turner T (2005) Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 92, 366 375.
67. Enomoto M, Utsumi M Park MK (2006) Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 147, 530 542.
68. von Alten J, Fister S, Schulz H, Viereck V, Frosch KH, Emons G Grundker C (2006) GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 100, 13 21.
69. Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y Levite M (2002) The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. Nat Med 8, 1421 1426.
70. Parborell F, Irusta G, Rodriguez Celin A Tesone M (2008) Regulation of ovarian angiogenesis and apoptosis by GnRH-I analogs. Mol Reprod Dev 75, 623 631.
71. Taylor PD, Hillier SG Fraser HM (2004) Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol 183, 1 17.
72. Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G Staibano S (2005) Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J Soc Gynecol Investig 12, 123 128.
73. Kraus S, Naor Z Seger R (2006) Gonadotropin-releasing hormone in apoptosis of prostate cancer cells. Cancer Lett 234, 109 123.
74. Imai A, Horibe S, Takagi A Tamaya T (1997) Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Am J Obstet Gynecol 176, 371 376.
75. Kraus S, Benard O, Naor Z Seger R (2003) c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem 278, 32618 32630.
76. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N et al. (1999) Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59, 5133 5142.
77. Kim KY, Choi KC, Park SH, Chou CS, Auersperg N Leung PC (2004) Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 89, 3020 3026.
78. Shah BH, Farshori MP, Jambusaria A Catt KJ (2003) Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 278, 19118 19126.
79. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179 185.
80. Kao S, Jaiswal RK, Kolch W Landreth GE (2001) Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem 276, 18169 18177.
81. Pouyssegur J, Volmat V Lenormand P (2002) Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64, 755 763.
82. Chakraborti S, Mandal M, Das S, Mandal A Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269 285.
83. Shah BH, Soh JW Catt KJ (2003) Dependence of gonadotropin-releasing hormone-induced neuronal MAPK signaling on epidermal growth factor receptor transactivation. J Biol Chem 278, 2866 2875.
84. Roelle S, Grosse R, Aigner A, Krell HW, Czubayko F Gudermann T (2003) Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem 278, 47307 47318.
85. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M Limonta P (1996) Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81, 3930 3937.
86. Grundker C, Volker P Emons G (2001) Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142, 2369 2380.
87. Eicke N, Gunthert AR, Emons G Grundker C (2006) GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol 29, 1223 1229.
88. Lamharzi N, Halmos G, Jungwirth A Schally AV (1998) Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 13, 429 435.
89. Montagnani Marelli M, Moretti RM, Mai S, Procacci P Limonta P (2007) Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30, 261 271.
90. Marelli MM, Moretti RM, Dondi D, Motta M Limonta P (1999) Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140, 329 334.
91. Lamharzi N, Schally AV Koppan M (1998) Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 77, 185 192.
92. Bifulco G, Miele C, Pellicano M, Trencia A, Ferraioli M, Paturzo F, Tommaselli GA, Beguinot F Nappi C (2004) Molecular mechanisms involved in GnRH analogue-related apoptosis for uterine leiomyomas. Mol Hum Reprod 10, 43 48.
93. Shah BH, Neithardt A, Chu DB, Shah FB Catt KJ (2006) Role of EGF receptor transactivation in phosphoinositide 3-kinase-dependent activation of MAP kinase by GPCRs. J Cell Physiol 206, 47 57.
94. Grundker C, Schulz K, Gunthert AR Emons G (2000) Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85, 3815 3820.
95. Sakamoto Y, Harada T, Horie S, Iba Y, Taniguchi F, Yoshida S, Iwabe T Terakawa N (2003) Tumor necrosis factor-alpha-induced interleukin-8 (IL-8) expression in endometriotic stromal cells, probably through nuclear factor-kappa B activation: gonadotropin-releasing hormone agonist treatment reduced IL-8 expression. J Clin Endocrinol Metab 88, 730 735.
96. Choi JR, Park DW, Choi DS Min CK (2006) Role of integrin, FAK (focal adhesion kinase) and ERK (extracellular signal regulated kinase) on the suppressed cell proliferation of endometrial cancer cells by GnRH (gonadotropin-releasing hormone). Korean J Fertil Steril 33, 115 123.
97. Chegini N Kornberg L (2003) Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma. J Soc Gynecol Investig 10, 21 26.
98. Maudsley S, Davidson L, Pawson AJ, Freestone SH, Lopez de Maturana R, Thomson AA Millar RP (2006) Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology 84, 285 300.
99. Kaiser UB, Conn PM Chin WW (1997) Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 18, 46 70.
100. Haisenleder DJ, Cox ME, Parsons SJ Marshall JC (1998) Gonadotropin-releasing hormone pulses are required to maintain activation of mitogen-activated protein kinase: role in stimulation of gonadotrope gene expression. Endocrinology 139, 3104 3111.
101. Krsmanovic LZ, Mores N, Navarro CE, Arora KK Catt KJ (2003) An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proc Natl Acad Sci USA 100, 2969 2974.
102. Loumaye E Catt KJ (1982) Homologous regulation of gonadotropin-releasing hormone receptors in cultured pituitary cells. Science 215, 983 985.
103. Liu F, Usui I, Evans LG, Austin DA, Mellon PL, Olefsky JM Webster NJ (2002) Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells. J Biol Chem 277, 32099 32108.
104. Krsmanovic LZ, Mores N, Navarro CE, Tomic M Catt KJ (2001) Regulation of Ca2+-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons. Mol Endocrinol 15, 429 440.
105. Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, Schultz G Gudermann T (2000) Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 275, 9193 9200.
106. Guo CH, Janovick JA, Kuphal D Conn PM (1995) Transient transfection of GGH3-1′ cells [GH3 cells stably transfected with the gonadotropin- releasing hormone (GnRH) receptor complementary deoxyribonucleic acid] with the carboxyl-terminal of beta-adrenergic receptor kinase 1 blocks prolactin release: evidence for a role of the G protein beta gamma-subunit complex in GnRH signal transduction. Endocrinology 136, 3031 3036.
107. Clapham DE Neer EJ (1993) New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 365, 403 406.
108. Federman AD, Conklin BR, Schrader KA, Reed RR Bourne HR (1992) Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits. Nature 356, 159 161.
109. Tang WJ Gilman AG (1991) Type-specific regulation of adenylyl cyclase by G protein beta gamma subunits. Science 254, 1500 1503.
110. Kaiser UB, Jakubowiak A, Steinberger A Chin WW (1993) Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology 133, 931 934.
111. Kang SK, Cheng KW, Nathwani PS, Choi KC Leung PC (2000) Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 13, 297 304.
112. Kaiser UB, Sabbagh E, Katzenellenbogen RA, Conn PM Chin WW (1995) A mechanism for the differential regulation of gonadotropin subunit gene expression by gonadotropin-releasing hormone. Proc Natl Acad Sci USA 92, 12280 12284.
113. McArdle CA, Gorospe WC, Huckle WR Conn PM (1987) Homologous down-regulation of gonadotropin-releasing hormone receptors and desensitization of gonadotropes: lack of dependence on protein kinase C. Mol Endocrinol 1, 420 429.
114. Lu ZL, Gallagher R, Sellar R, Coetsee M Millar RP (2005) Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. J Biol Chem 280, 29796 29803.
115. Lu ZL, Coetsee M, White CD Millar RP (2007) Structural determinants for ligand-receptor conformational selection in a peptide G protein-coupled receptor. J Biol Chem 282, 17921 17929.
116. Shimizu M Bedecarrats GY (2006) Identification of a novel pituitary-specific chicken gonadotropin-releasing hormone receptor and its splice variants. Biol Reprod 75, 800 808.
117. Zhou W Sealfon SC (1994) Structure of the mouse gonadotropin-releasing hormone receptor gene: variant transcripts generated by alternative processing. DNA Cell Biol 13, 605 614.
118. Kottler ML, Bergametti F, Carre MC, Morice S, Decoret E, Lagarde JP, Starzec A Counis R (1999) Tissue-specific pattern of variant transcripts of the human gonadotropin-releasing hormone receptor gene. Eur J Endocrinol 140, 561 569.
119. Grosse R, Schoneberg T, Schultz G Gudermann T (1997) Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol Endocrinol 11, 1305 1318.
120. Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH Choi WS (1998) Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 26, 259 264.
121. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P Halmos G (2001) Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 12, 761 768.
122. Osborne CK, Hobbs K Trent JM (1987) Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 9, 111 121.
123. Dickson RB, Bates SE, McManaway ME Lippman ME (1986) Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46, 1707 1713.
124. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J Koeffler HP (2001) Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276, 14187 14194.
125. Yao JJ, Liu Y, Lacorazza HD, Soslow RA, Scandura JM, Nimer SD Hedvat CV (2007) Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene 26, 4032 4037.
126. Hongo A, Kuramoto H, Nakamura Y, Hasegawa K, Nakamura K, Kodama J Hiramatsu Y (2003) Antitumor effects of a soluble insulin-like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo. Cancer Res 63, 7834 7839.
127. Webber MM, Bello D Quader S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 30, 58 64.
128. Sobel RE Sadar MD (2005) Cell lines used in prostate cancer research: a compendium of old and new lines - part 1. J Urol 173, 342 359.
129. Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N Inoue M (2003) Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 163, 2259 2269.
130. Tanaka R, Saito T, Ashihara K, Nishimura M, Mizumoto H Kudo R (2003) Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells. Gynecol Oncol 90, 297 304.
131. Sillem M, Prifti S, Koumouridis A Runnebaum B (1999) Invasiveness corresponds to differentiation rather than to proteinase secretion in endometrial cancer cell lines. Eur J Gynaecol Oncol 20, 367 370.
132. Stone KR, Mickey DD, Wunderli H, Mickey GH Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274 281.
133. Honjo Y, Nangia-Makker P, Inohara H Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7, 661 668.
134. Mukhopadhyay R, Theriault RL Price JE (1999) Increased levels of alpha6 integrins are associated with the metastatic phenotype of human breast cancer cells. Clin Exp Metastasis 17, 325 332.
135. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME et al. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150, 534 544.
136. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43, 5379 5389.
137. Maeda T, Tashiro H, Katabuchi H, Begum M, Ohtake H, Kiyono T Okamura H (2005) Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer 93, 116 123.
138. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R et al. (2001) A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98, 9636 9641.
139. Illing N, Troskie BE, Nahorniak CS, Hapgood JP, Peter RE Millar RP (1999) Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (Carassius auratus). Proc Natl Acad Sci USA 96, 2526 2531.
140. Neill JD, Duck LW, Sellers JC Musgrove LC (2001) A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 282, 1012 1018.
141. Neill JD (2002) GnRH and GnRH receptor genes in the human genome. Endocrinology 143, 737 743.
142. Eicke N, Gunthert AR, Viereck V, Siebold D, Behe M, Becker T, Emons G Grundker C (2005) GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. Eur J Endocrinol 153, 605 612.
143. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR Millar RP (2003) A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144, 423 436.
144. Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z Millar RP (2007) Mammalian type I GnRH receptors undergo slow, constitutive, agonist-independent internalization. Endocrinology 149, 1415 1422.
145. Finch AR, Green L, Hislop JN, Kelly E McArdle CA (2004) Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone
146. Okada Y, Murota-Kawano A, Kakar SS Winters SJ (2003) Evidence that gonadotropin-releasing hormone (GnRH) II stimulates luteinizing hormone and follicle-stimulating hormone secretion from monkey pituitary cultures by activating the GnRH I receptor. Biol Reprod 69, 1356 1361.
147. Kauffman AS, Wills A, Millar RP Rissman EF (2005) Evidence that the type-2 gonadotrophin-releasing hormone (GnRH) receptor mediates the behavioural effects of GnRH-II on feeding and reproduction in musk shrews. J Neuroendocrinol 17, 489 497.
148. van Biljon W, Wykes S, Scherer S, Krawetz SA Hapgood J (2002) Type II gonadotropin-releasing hormone receptor transcripts in human sperm. Biol Reprod 67, 1741 1749.
149. Maiti K, Oh DY, Moon JS, Acharjee S, Li JH, Bai DG, Park HS, Lee K, Lee YC, Jung NC et al. (2005) Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death. J Clin Endocrinol Metab 90, 4287 4298.
150. Yahalom D, Chen A, Ben-Aroya N, Rahimipour S, Kaganovsky E, Okon E, Fridkin M Koch Y (1999) The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. FEBS Lett 463, 289 294.